Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Rhea-AI Summary
Absci (Nasdaq: ABSI) appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer effective March 3, 2026 to lead clinical development of its AI-designed therapeutics, including flagship ABS-201. Chief Innovation Officer Andreas Busch, Ph.D. will retire March 31, 2026 and transition to co-chair Absci’s Scientific Advisory Board.
Dr. Somaratne joins from Vertex and has prior leadership at BioMarin and Amgen, with experience on Roctavian, Repatha, and Journavx.
Positive
- Appointed experienced CMO Ransi Somaratne, effective March 3, 2026
- Dr. Somaratne brings prior senior roles at Vertex, BioMarin, and Amgen
- CMO will lead clinical strategy for flagship program ABS-201
- Andreas Busch will continue advising as co-chair of the Scientific Advisory Board
Negative
- Chief Innovation Officer Andreas Busch to retire from executive role March 31, 2026
News Market Reaction – ABSI
On the day this news was published, ABSI declined 8.21%, reflecting a notable negative market reaction. This price movement removed approximately $38M from the company's valuation, bringing the market cap to $421M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ABSI gained 2.19% while key peers showed mixed moves (e.g., CGEM +5.06%, INBX +6.91%, LXRX +9.86% but also flagged in momentum scanner as -5.13% intraday). With limited synchronous moves and no same-day peer news, trading appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings date notice | Neutral | +2.3% | Announced timing for Q4 and full-year 2025 results and business update. |
| Feb 17 | Investor conferences | Positive | +4.3% | Planned participation in several March 2026 investor conferences and webcasts. |
| Dec 16 | JP Morgan conference | Positive | +4.7% | Presentation at 44th J.P. Morgan Healthcare Conference on AI-driven programs. |
| Dec 11 | ABS-201 data update | Positive | -3.3% | Reported new human ex vivo ABS-201 data suggesting hair follicle regeneration potential. |
| Dec 10 | Patient advocacy partnership | Positive | +12.8% | Partnered with Landon Donovan to highlight ABS-201 and hair loss unmet needs. |
Recent news, especially on partnerships and visibility events, more often coincided with positive price reactions, with one notable selloff on favorable ABS-201 data.
Over the last six months, Absci’s news flow has focused on visibility events and its AI-designed pipeline. An ABS-201 hair growth data update on Dec 11, 2025 saw a -3.27% move despite positive scientific details, while a patient-focused ABS-201 partnership on Dec 10, 2025 corresponded to a 12.78% gain. Participation in major conferences, including J.P. Morgan in Jan 2026, and multiple investor events in Feb 2026, also aligned with upward moves. Today’s CMO appointment fits this pattern of strengthening the clinical story around ABS-201 and the broader AI-driven pipeline.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 12, 2025 allows Absci to register up to $400,000,000 in various securities, including up to $100,000,000 of common stock under a sales agreement with TD Securities (USA) LLC. The filing is preliminary and not yet effective, with proceeds designated for general corporate purposes. No usage has been reported to date.
Market Pulse Summary
The stock moved -8.2% in the session following this news. A negative reaction despite leadership strengthening would fit past instances where strong scientific updates, such as the ABS-201 data on Dec 11, 2025, preceded a -3.27% decline. The market has sometimes faded positive pipeline developments after initial enthusiasm. While adding an experienced CMO may improve execution prospects around ABS-201 and other programs, prior behavior suggests investors can de-risk on news rather than reward it, especially when capital-raising flexibility exists via a large registration statement.
Key Terms
gene therapy medical
pcsk9 inhibitor medical
clinical proof of concept technical
AI-generated analysis. Not financial advice.
Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline
Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board
VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci’s expanding pipeline of AI-designed therapeutics.
Dr. Somaratne is a physician-scientist and seasoned biopharmaceutical executive who joins Absci from Vertex Pharmaceuticals, where he served as Senior Vice President of Clinical Development. He previously held various scientific leadership roles at BioMarin Pharmaceutical and Amgen.
“Ransi is a proven clinical leader, and we’re excited to have him join Absci at a moment when our AI-designed pipeline is rapidly advancing through clinical development,” said Sean McClain, Founder & CEO of Absci. “His wealth of experience will enhance our clinical development strategy and execution capabilities as we advance multiple programs, including our flagship ABS-201 program toward clinical proof of concept.”
A cardiologist and internist by training, Dr. Somaratne’s career is defined by work on multiple pioneering clinical development programs, including the Hemophilia A gene therapy RoctavianⓇ, the development and global approvals of a PCSK9 inhibitor RepathaⓇ, and the development and approval of JournavxⓇ, the first NaV1.8 inhibitor approved for moderate to severe acute pain. He earned his Doctor of Medicine (MD) degree from Albany Medical College in Albany, NY, and also holds a Masters in Business Administration (MBA) from the University of North Carolina at Chapel Hill. He has co-authored over 30 papers in peer-reviewed medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association.
“I am excited to join Absci at such a pivotal moment, when the AI Drug Creation Engine has already yielded multiple clinical-stage programs,” said Ransi Somaratne. “I look forward to advancing the development of a truly innovative pipeline of therapeutics with the potential to transform the lives of patients with significant unmet clinical need.”
Alongside Dr. Somaratne’s appointment, Absci announced the retirement of Professor Andreas Busch, Ph.D.. As Chief Innovation Officer, Professor Busch was a driving force in building Absci’s AI-designed therapeutics pipeline, most notably in the discovery and development of ABS-201. Professor Busch will transition from his executive duties on March 31, 2026 to co-chair Absci’s Scientific Advisory Board, where he will continue to provide scientific and strategic advice and oversight to the company.
“We are deeply grateful to Andreas for his immense contributions and leadership during a foundational period for Absci,” said Sean McClain, Founder and CEO. “His vision was the catalyst for our ABS-201 program. He leaves behind a legacy of innovation that will continue to guide our mission as we advance these potentially life-changing therapies through the clinic.”
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, Headline™ and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Media Contact:
press@absci.com
Investor Contact:
Alex Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com
FAQ
Who is Absci's new Chief Medical Officer and when did the appointment occur (ABSI)?
What clinical programs will CMO Ransi Somaratne oversee at Absci (ABSI)?
What is Ransi Somaratne’s background before joining Absci (ABSI)?
What is happening to Absci’s Chief Innovation Officer Andreas Busch (ABSI)?
How might the leadership changes affect Absci’s clinical progress, especially ABS-201 (ABSI)?
